Takeda Global Headquarters Grand Opening
Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.
At the grand opening, Creative Director Kashiwa Sato (SAMURAI, Inc.), Takeda's President and CEO Christophe Weber, and Takeda’s Head of Corporate Strategy and the CEO Office, Yasuhiro Fukutomi, who managed the project, took to the stage to introduce the objectives and significance of the project as the company accelerates its transformation.
“Takeda Global Headquarters symbolizes the passing on to the next generation of Takeda's unwavering identity and values as a company, with its roots in Japan, yet reaching patients worldwide," said Takeda President and CEO Weber. "Moreover, it will provide a base for our diverse workforce of around 30,000 employees across the globe where they can connect, collaborate, learn and share, in an environment designed to offer comfort and inspiration. From here in Nihonbashi, Tokyo, we will pursue our mission of contributing to better health and a brighter future for people worldwide, while nurturing our relationship with the local community.”
Kashiwa Sato said “I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s values, and its core commitment to always put patients first. In this process, I chose 'life force' as the central concept, and the eight characters for 'life', 'water', 'light', 'earth', 'trees', 'people', 'connections', and 'future' as motifs, representing this concept. Just as these basic natural elements form the wellspring that nurtures life, the bonds between people are the driving-force that enable them to tackle the biggest of challenges, and contribute to a brighter future for all. It is my hope that this building will be an inspiration to all who work here as well as to the visitors, and it will lead them to naturally want to share their thoughts on Takeda’s future.”
With Takeda Global Headquarters as a base, and a symbol of our values, we will further accelerate our transformation into becoming a global, values-based R&D-driven biopharmaceutical leader.
About Takeda Global Headquarters
Please visit the URL below for more information on Takeda Global
As the embodiment of a global brand with roots in Japan, I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s DNA. These fundamental elements contribute to Takeda being the world-renowned pharmaceutical company, as well as underpinning the promise of a brighter future for all. They could also be interpreted as people’s “life force”, and it was this that I selected as the overall concept for the interior design. The concept of “life force” can also be seen to represent the fundamental point of origin of the company, and indeed, refined to reveal a vision of its future state. In this way, it can hold an important message for Takeda, and one that should be embraced and passed on to future generations. I approached the flow of movement, from the building entrance, past the reception and then on to the areas where people work, as a story of nurturing life. I chose to depict phases in this story - beginning with the source of life, followed by growth, and finally to the formation of strong connections - by associating symbolic kanji characters with each space. The characters were tuned into modern designs that convey the spirit of ”Wa” (a sense of Japanese-style harmony) which is inherent in Takeda, and applied as artwork on the walls. It is my hope that this building will be an inspiration to all who work here, and will lead them to naturally want to share their thoughts on Takeda’s future with other people that they meet on a daily basis.
Kashiwa Sato, Creative Director
Photos are available upon request.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:
4502) is a global, research and development-driven pharmaceutical
company committed to bringing better health and a brighter future to
patients by translating science into life-changing medicines. Takeda
focuses its R&D efforts on oncology, gastroenterology and neuroscience
therapeutic areas plus vaccines. Takeda conducts R&D both internally and
with partners to stay at the leading edge of innovation. Innovative
products, especially in oncology and gastroenterology, as well as
Takeda’s presence in emerging markets, are currently fueling the growth
of Takeda. Approximately 30,000 Takeda employees are committed to
improving quality of life for patients, working with Takeda’s partners
in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0) 3-3278-2095
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati